Aarti Drugs Ltd, part of the Aarti Group of Industries, engaged in manufacturing APIs, pharma intermediates, specialty chemicals, and formulations, reported strong results for Q2FY26.
Financial Highlights:
- Revenues increased 9.2% year-on-year to ₹653 crore from ₹598 crore.
- Total expenses rose 7.04% to ₹593 crore from ₹554 crore.
- Consolidated net profit climbed 28.57% to ₹45 crore from ₹35 crore.
- Earnings per share improved 29.40% to ₹4.93 from ₹3.81.
Profit growth was fuelled by higher sales volumes, improved operational efficiencies, and effective cost management.
Outlook:
Aarti Drugs is focused on expanding its product portfolio, strengthening exports, and investing in capacity enhancements and process improvements to sustain long-term growth.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.